Nevertheless, cell viability was notably reduced in cisplatin-treated HCT-116/DDP cells in the absence of PRAP1 (10 μM: P=0.0292, P<0.0001; 20 μM: P=0.0145, P=0.0014, P<0.0001) (Fig. 2C-2D), suggesting that PRAP1 downregulation could sensitize cisplatin-resistant CRC cells to cisplatin. Here, PRAP1 is linked to colorectal carcinoma.